Recombinant C1-inhibitor: Effects on coagulation and fibrinolysis in patients with hereditary angioedema

BioDrugs

Volumn 26, Issue 1, 2012, Pages 43-52

  Relan, Anurag ^a   Bakhtiari, Kamran ^b   Van Amersfoort, Edwin S ^a   Meijers, Joost C M ^b   Hack, C Erik ^c  

^a Pharming Group NV   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

angioedema; attack; coagulation; fibrinolysis; recombinant human C1 inhibitor; thrombo embolic adverse event

Indexed keywords

ANTIPLASMIN; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1S INHIBITOR; D DIMER; PLASMIN; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANGIOEDEMAS, HEREDITARY; BLOOD COAGULATION; COMPLEMENT C1 INHIBITOR PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; RECOMBINANT PROTEINS; THROMBOEMBOLISM;

EID: 84855647895     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11599490-000000000-00000     Document Type: Article

References (42)

1. Zuraw BJ. Hereditary angioedema. N Engl J Med 2008; 359: 1027-36
2. Bygum A. Hereditary angio-edema in Denmark: A nationwide survey. Br J Dermatol 2009; 161: 1153-8
3. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: A broad review for clinicians. Arch Intern Med 2001; 161: 2417-297
4. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71: 206-15
5. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: The clinical syndrome and its management. Ann Intern Med 1976; 84: 580-93
6. Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000; 75: 349-54 (Pubitemid 30187107)
7. Cicardi M, Zingale LC, Zanichelli A, et al. The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema. Expert Opin Pharmacother 2007; 8: 3173-81
8. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-8
9. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-22
10. Arzneimittelkommission der deutschen Arzteschaft. Schwerwiegende Thrombenbildung nach Berinert HS. Deutsches Ärzteblatt 2000 Apr; 97 (Heft 15): A-1016
11. Buehler PW. Cinryze pharmacology/toxicology review memorandum, Food and Drug Administration, December 2007 [online]. Available fromURL: http://www. fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/Approved Products/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM229783. pdf [Accessed 2011 Sep 26]
12. Cinryze: full prescribing information, update 2010Nov [online].Available from URL: http://www.cinryze.com/documents/cinryze-prescribing-information.pdf [Accessed 2011 Sep 26]
13. Berinert: full prescribing information, update 2009 Nov [online]. Available from URL: http://www.berinert.com/docs/berinert-pi.pdf [Accessed 2011 Sep 26]
14. Food and Drug Administration. Potential signals of serious risks/new safety information identified by the Adverse Event Reporting System (AERS) 2010 Jan-Mar [online]. Available from URL: http://www.fda.gov/Drugs/Gui danceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm216272. htm [Accessed 2011 Sep 26]
15. Bock SC, Skriver K, Nielsen E, et al. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 1986; 25: 4292-301 (Pubitemid 16054244)
16. Bos IG, Hack CE, Abrahams JP. Structural and functional aspects of C1-inhibitor. Immunobiology 2002; 205: 518-33 (Pubitemid 35153966)
17. Wuillemin WA, Eldering E, Citarella F, et al. Modulation of contact system proteases by glycosaminoglycans: selective enhancement of the inhibition of factor XIa. J Biol Chem 1996; 271: 12913-8 (Pubitemid 26175865)
18. Cugno M, Bos I, Lubbers Y, et al. In vitro interaction of C1-inhibitor with thrombin. Blood Coagul Fibrinolysis 2001; 12: 253-60 (Pubitemid 32575157)
19. Eldering E, Huijbregts CC, Lubbers YT, et al. Characterization of recombinant C1 inhibitor P1 variants. J Biol Chem 1992; 267: 7013-20
20. Sulikowski T, Patston PA. The inhibition of TNK-t-PA by C1-inhibitor. Blood Coagul Fibrinolysis 2001; 12: 75-7 (Pubitemid 32150255)
21. Horstick G, Berg O, Heimann A, et al. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation 2001; 104: 3125-31 (Pubitemid 34014069)
22. Nuijens JH, Hack CE. Recombinant C1 inhibitor. J Allergy Clin Immunol 2004; 114: S100-4
23. Van Doorn MBA, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005; 116: 876-83 (Pubitemid 41400555)
24. Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attack. Transfusion 2007; 47: 1028-32 (Pubitemid 46802091)
25. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126: 821-7
26. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema.NEngl J Med 2002; 347: 621-2
27. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998; 351: 1693-7 (Pubitemid 28254530)
28. Cugno M, Hack CE, de Boer JP, et al. Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med 1993; 121: 38-43 (Pubitemid 23081757)
29. Cugno M, Cicardi M, Bottasso B, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997; 89: 3213-8
30. CugnoM, ZanichelliA, BellatorreAG, et al. Plasmabiomarkersof acuteattacks in patients with angioedema due to C1-inhibitor deficiency. Allergy 2009; 64: 254-7
31. Pixley RA, Schapira M, Colman RW. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem 1985; 260 (3): 1723-9 (Pubitemid 15145450)
32. Chan JY, Burrowes CE, Habal FM, et al. The inhibition of activated factor XII (Hageman factor) by antithrombin III: The effect of other plasma proteinase inhibitors. Biochem Biophys Res Commun 1977; 74: 150-8 (Pubitemid 8012971)
33. van der Graaf F, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest 1983; 71: 149-58 (Pubitemid 13170247)
34. Schapira M, Scott CF, Colman RW. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. JClin Invest 1982; 69: 462-8 (Pubitemid 12177625)
35. Wuillemin WA, Minnema M, Meijers JC, et al. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 1995; 85: 1517-26
36. Eldering E, Huijbregts CC, Lubbers YT, et al. Characterization of recombinant C1 inhibitor P1 variants. J Biol Chem 1992; 267: 7013-20
37. Wiman B, Boman L, Collen D. On the kinetics of the reaction between human antiplasmin and a low-molecular-weight form of plasmin. Eur J Biochem 1978; 87: 143-6 (Pubitemid 8360576)
38. Caliezi C, Wuillemin WA, Zeerleder S, et al. C1-Esterase inhibitor: an antiinflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000; 52: 91-112 (Pubitemid 30127596)
39. Rau JC, Beaulieu LM, Huntington JA, et al. Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 2007; 5 Suppl. 1: 102-15 (Pubitemid 46958823)
40. Edelberg JM, Reilly CF, Pizzo SV. The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1: The effects of fibrinogen, heparin, vitronectin, and lipoprotein (a). J Biol Chem 1991; 266: 7488-93 (Pubitemid 21906391)
41. Gurewich V, Pannell R. Recombinant human C1- inhibitor prevents nonspecific proteolysis by mutant pro-urokinase during optimal fibrinolysis. Thromb Haemost 2009; 102: 279-86
42. Pannell R, Kung W, Gurewich V. C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis. J Thromb Haemost 2007; 5: 1047-54 (Pubitemid 46691736)